Slide 1: 2026 1Q Earnings Release
CELL BIOTECH Probiotics & Microbiome company 2026 1Q Earnings Release 2026. 05. As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes wi prior notice due to the external audit process, and may cause the actual results to
Slide 2: Revenue up 30% to KRW 14.6 billion, operating profit up 134%
CELL BIOTECH Revenue up 30% to KRW 14.6 billion, operating profit up 134% to KRW 3.2 billion Domestic revenue up 14.8%, overseas revenue up 43.8% Duolac brand sales up 20% to KRW 7.7 billion, OEM/ODM sales up 60% to KRW 7.3 billion, Raw material sales down -33% to KRW 0.9 billion (unit : KRW 100 mil
Slide 3: Q1 revenue KRW 14.6 billion, yoy +30%, qoq -0.2%
CELL BIOTECH Q1 revenue KRW 14.6 billion, yoy +30%, qoq -0.2% Quarterly revenue Full year revenue (unit : KRW mil) (unit : KRW mil) 3
Slide 4: Q1 operating profit KRW 3.2 billion, yoy +134%
CELL BIOTECH Q1 operating profit KRW 3.2 billion, yoy +134% Net Profit KRW +5.3 billion, yoy +158% Quarterly profit Full year profit (unit : KRW mil) 4
Slide 5: Q1 revenue of Duolac brand, OEM/ODM and raw material
CELL BIOTECH Q1 revenue of Duolac brand +20% to 7.7 KRW bil., OEM/ODM +73% to 6.0 KRW bil., and raw material -0.2% to 0.9 KRW bil. (unit : KRW mil) 5
Slide 6: Business update
Business update CELL BIOTECH Microbiome R&D nee in global export for 12 consecutive 1) Microbiome First-in-Class anticancer pipeline ‘PP-P8’ clinical phase 1 IND submitted (Mar 5, 2021) 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 in the world for 12 consecutive years 2) Acquisition European pa
Slide 7: FDA GRAS World's Most Listed
CELL BIOTECH FDA GRAS World’s Most Listed 1) Cellbiotech "11 types of lactic acid bacteria 2) Cellbiotech, Probiotics Leading... Global Leap secured FDA GRAS certification... The World's Largest Holdings" https://www.hankyung.com/article/202402222016i https://www.dailypharm.com/Users/News/NewsVie w.
Slide 8: Cellbiotech's Duolac Achieves No. 1 Market Share in Denmark
CELL BIOTECH “Now is the Era of K-Probiotics” – Cellbiotech’s ‘Duolac’ Achieves No. 1 Market Share in Denmark, the Home Country 1) Surpassing Local Brand ‘Lactocare’ --- Assuming the Top Spot with a 46.6% Market Share https://n.news.naver.com/mnews/article/016/000261 4577?sid=101 8
Slide 9: Income statement and statement of financial position
CELL BIOTECH Income statement Statement of financial position (unit : KRW 100 mil., %) (unit : KRW 100 mil., %) 2025 1q 2026 1q 2025 .12 2026 1q Assets 1,366 1,433 Amount Ratio Amount Ratio Current Assets 1037 1,070 Revenue 112.3 100.0 146.0 100.0 Non current Assets 329 363 Gross profit 79.8 71.1 10